Clozapine in the Treatment of Aggression in Conduct Disorder in Children and Adolescents: A Randomized, Double-blind, Controlled Trial
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: This study was conducted to compare the efficacy of clozapine vs. risperidone in the treatment of aggression in conduct disorder in children and adolescents. Methods: Twenty-four children with conduct disorder aged 6 to 16 years were randomized in a prospective, double- blind trial into two groups to receive clozapine or risperidone for 16 weeks. The Modified Overt Aggression Scale score was used as the primary outcome of the study. Secondary outcomes were Child Behavior Checklist (CBCL) externalization (CBCL-E) and internalization factors; Aggression, Hyperactivity and Delinquency subscales of CBCL-E, Child Global Assessment Scale (CGAS), Barnes Akathisia Rating Scale, and Simpson-Angus Scale. Results: Both antipsychotics were similarly effective in the primary outcome and in most of the secondary ones. Clozapine was more effective in CBCL-E, the delinquency subscale and the CGAS scores than risperidone (p =0.039, 0.010, and 0.021). Two subjects from the clozapine group were excluded due to a low neutrophil count at week four. Conclusion: Clozapine and risperidone are effective for short-term treatment of aggression in children and adolescents with conduct disorder. Clozapine was more effective than risperidone in conduct externalization factors, delinquency trait and global functioning in children and adolescents. Stronger efficacy of clozapine should be investigated in larger sample sizes using pharmacogenomic studies. White blood cell counts need to be monitored when prescribing clozapine.
Abstract
Objective: This study was conducted to compare the efficacy of clozapine vs. risperidone in the treatment of aggression in conduct disorder in children and adolescents. Methods: Twenty-four children with conduct disorder aged 6 to 16 years were randomized in a prospective, double- blind trial into two groups to receive clozapine or risperidone for 16 weeks. The Modified Overt Aggression Scale score was used as the primary outcome of the study. Secondary outcomes were Child Behavior Checklist (CBCL) externalization (CBCL-E) and internalization factors; Aggression, Hyperactivity and Delinquency subscales of CBCL-E, Child Global Assessment Scale (CGAS), Barnes Akathisia Rating Scale, and Simpson-Angus Scale. Results: Both antipsychotics were similarly effective in the primary outcome and in most of the secondary ones. Clozapine was more effective in CBCL-E, the delinquency subscale and the CGAS scores than risperidone (p =0.039, 0.010, and 0.021). Two subjects from the clozapine group were excluded due to a low neutrophil count at week four. Conclusion: Clozapine and risperidone are effective for short-term treatment of aggression in children and adolescents with conduct disorder. Clozapine was more effective than risperidone in conduct externalization factors, delinquency trait and global functioning in children and adolescents. Stronger efficacy of clozapine should be investigated in larger sample sizes using pharmacogenomic studies. White blood cell counts need to be monitored when prescribing clozapine.
참고문헌 (57)
- Loy JH, "Atypical antipsychotics for disruptive behavior disorders in children and youths", Cochrane Database Syst Rev, (9), pp.CD008559~ (2017)
- Thomas CR, "Dulcan’s textbook of child and adolescent psychiatry", pp.195~218 (2016), American Psychiatric Association Publishing
- Gurnani T, "Pharmacotherapy of aggression in child and adolescent psychiatric disorders", J Child Adolesc Psychopharmacol, 26, pp.65~73 (2016)
- Pringsheim T, "The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention- deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: Antipsychotics and traditional mood stabilizers", Can J Psychiatry, 60, pp.52~61 (2015)
- Costello EJ, "10-year research update review: the epidemiology of child and adolescent psychiatric disorders: I. Methods and public health burden", J Am Acad Child Adolesc Psychiatry, 44, pp.972~986 (2005)
- Medina-Mora ME, "[Prevalence of mental disorders and use of services : Results of national survey of psychiatric epidemiology in Mexico", Salud Ment, 26, pp.1~16 (2003)
- Dayton CJ, "Development and socialization of physical aggression in very young boys", Infant Ment Health J, 38, pp.150~165 (2017)
- Schur SB, "Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review", J Am Acad Child Adolesc Psychiatry, 42, pp.132~144 (2003)
- Pappadopulos E, "Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY)", Part II. J Am Acad Child Adolesc Psychiatry, 42, pp.145~161 (2003)
- Cheng-Shannon J, "Second-generation antipsychotic medications in children and adolescents", J Child Adolesc Psychopharmacol, 14, pp.372~394 (2004)
- Findling RL, "Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder", J Am Acad Child Adolesc Psychiatry, 45, pp.792~800 (2006)
- Findling RL, "Is there a role for clozapine in the treatment of children and adolescents", J Am Acad Child Adolesc Psychiatry, 46, pp.423~428 (2007)
- Steiner H, "Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder", J Am Acad Child Adolesc Psychiatry, 46, pp.126~141 (2007)
- McVoy M, "Child and adolescent psychopharmacology update", Psychiatr Clin North Am, 32, pp.111~133 (2009)
- Teixeira EH, "Atypical antipsychotics in the treatment of pathological aggression in children and adolescents : literature review and clinical recommendations", Trends Psychiatry Psychother, 35, pp.151~159 (2013)
- Teixeira EH, "Clozapine in severe conduct disorder", J Child Adolesc Psychopharmacol, 23, pp.44~48 (2013)
- Brown D, "Clozapine : an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital", CNS Spectr, 19, pp.391~402 (2014)
- Stahl SM, "Sthal´s essential psychopharmacology: neuroscientific basis and practical application", pp.180~202 (2014), Grupo Aula Médica, S.L
- Kant R, "The off-label use of clozapine in adolescents with bipolar disorder, intermittent explosive disorder, or posttraumatic stress disorder", J Child Adolesc Psychopharmacol, 14, pp.57~63 (2004)
- McEvoy JP, "Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment", Am J Psychiatry, 163, pp.600~610 (2006)
- Sauvaget A, "Anti-aggressiveness effects of clozapine on complex neuropsychiatric pathologies", Ann Méd Psychol, 167, pp.285~289 (2009)
- Lambrey S, "Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder", J Child Adolesc Psychopharmacol, 20, pp.79~80 (2010)
- Asenjo Lobos C, "Clozapine versus other atypical antipsychotics for schizophrenia", Cochrane Database Sust Rev, (11), pp.CD006633~ (2010)
- Frogley C, "A systematic review of the evidence of clozapine's anti-aggressive effects", Int J Neuropsychopharmacol, 15, pp.1351~1371 (2012)
- Sanz-Fuentenebro J, "Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year", Schizophr Res, 149, pp.156~161 (2013)
- Fitzpatrick SE, "Aggression in autism spectrum disorder : presentation and treatment options", Neuropsychiatr Dis Treat, 12, pp.1525~1538 (2016)
- Solmi M, "Safety, tolerability, and risks associated with first-and second-generation antipsychotics : a state-of-the-art clinical review", Ther Clin Risk Manag, 13, pp.757~777 (2017)
- Kapur S, "Does fast dissociation from the dopamine d(2)receptor explain the action of atypical antipsychotics? : A new hypothesis", Am J Psychiatry, 158, pp.360~369 (2001)
- Natesan S, "Amisulpride the 'atypical' atypical antipsychotic-comparison to haloperidol, risperidone and clozapine", Schizophr Res, 105, pp.224~235 (2008)
- Gerbino-Rosen G, "Hematological adverse events in clozapine-treated children and adolescents", J Am Acad Child Adolesc Psychiatry, 44, pp.1024~1031 (2005)
- Nooijen PM, "Haematological toxicity of clozapine and some other drugs used in psychiatry", Hum Psychopharmacol, 26, pp.112~119 (2011)
- Cohen D, "White blood cell monitoring during long-term clozapine treatment", Am J Psychiatry, 170, pp.366~369 (2013)
- de With SA, "Genome-wide association study of lymphoblast cell viability after clozapine exposure", Am J Genet B Neuropsychiatr Genet, 168B, pp.116~122 (2015)
- Saito T, "Pharmacogenomic study of clozapine-induced agranulocytosis", granulocytopenia in a Japanese population, 2016, pp.80, 636~642
- Findling RL, "A double-blind pilot study of risperidone in the treatment of conduct disorder", J Am Acad Child Adolesc Psychiatry, 39, pp.509~516 (2000)
- Turgay A, "Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs", Pediatrics, 110, pp.e34~ (2002)
- Croonenberghs J, "Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients", J Am Acad Child Adolesc Psychiatry, 44, pp.64~72 (2005)
- Reyes M, "A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders", Am J Psychiatry, 163, pp.402~410 (2006)
- Pandina GJ, "Risperidone and cognitive function in children with disruptive behavior disorders", Biol Psychiatry, 62, pp.226~234 (2007)
- Aman MG, "What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit", hyperactivity disorder, 2014, pp.53, 47~60
- Gadow KD, "Risperidone added to parent training and stimulant medication : effects on attention-deficit", hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression, 2014, pp.53, 948~959
- Gadow KD, "Severely aggressive children receiving stimulant medication versus stimulant and risperidone : 12-month follow-up of the TOSCA trial", J Am Acad Child Adolesc Psychiatry, 55, pp.469~478 (2016)
- Sevcan Karakoç Demirkaya, "A Retrospective Study of Long Acting Risperidone Use to Support Treatment Adherence in Youth with Conduct Disorder", Clinical Psychopharmacology and Neuroscience, 15(4), pp.328~336 (2017), 대한정신약물학회[DOI]
- Ulku Akyol Ardic, "Efficacy and Safety Profile of Risperidone Long-acting Injection in Adolescents in a Real-life Setting", Clinical Psychopharmacology and Neuroscience, 16(1), pp.57~61 (2018), 대한정신약물학회[DOI]
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (2000), American Psychiatric Association
- Yudofsky SC, "The Overt Aggression Scale for the objective rating of verbal and physical aggression", Am J Psychiatry, 143, pp.35~39 (1986)
- Kay SR, "Profiles of aggression among psychiatric patients. I. Nature and prevalence", J Nerv Ment Dis, 176, pp.539~546 (1988)
- Silver JM, "The Overt Aggression Scale : overview and guiding principles", J Neuropsychiatry Clin Neurosci, 3, pp.S22~S29 (1991)
- "Clínica y Salud", 1997, 447~480
- Shaffer D, "A children's global assessment scale(CGAS)", Arch Gen Psychiatry, 40, pp.1228~1231 (1983)
- Barnes TR, "A rating scale for drug-induced akathisia", Br J Psychiatry, 154, pp.672~676 (1989)
- Simpson GN, "A rating scale for extrapyramidal side effects", Acta Psychiatr Scand, 212, pp.11~19 (1970)
- "Clorpromazina"[URL]
- Tschen AC, "The cytotoxicity of clozapine metabolites : implications for predicting clozapine-induced agranulocytosis", Clin Pharmacol Ther, 65, pp.526~532 (1999)
- Maher KN, "Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia", J Child Adolesc Psychopharmacol, 23, pp.110~116 (2013)
- Maayan L, "Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents", J Child Adolesc Psychopharmacol, 21, pp.517~535 (2011)